Finnovate Acquisition Corp. announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “FNVTU” Thursday, November 3.
The new SPAC intends to focus its search on fintech companies that are domiciled in Israel, that carry out all or a substantial portion of their activities in Israel, or that have some other significant Israeli connection. Finnovate is managed by Prof. David Gershon (former founder and CEO of SuperDerivatives) who will serve as Chairman and CEO, Ron Golan (former head of investment banking and capital markets at Morgan Stanley for Israel & CEE) will serve as Director and CFO, and Jonathan Ophir (Former Head of Credit Division, at Altshuler Shaham) will serve as CIO. Uri Chaitchik will serve as a senior consultant to the Company. The Company’s independent directors are Mitch Garber (former CEO of Caesars Acquisition Company), Gustavo Schwed (Former Partner at Morgan Stanley Private Equity and Providence Equity Partners) and Nadav Zohar (Chairman of LRC Europe).
Total SPAC deal count for 2021 year-to-date is now 513. This offering is expected to close on Monday, November 8.
EarlyBirdCapital, Inc. is serving as sole book-running manager for the offering. McDermott Will & Emery LLP is serving as Issuer’s Counsel with Graubard Miller serving as Underwriter’s Counsel. Marcum, LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...
At the SPAC of Dawn Ever since Digital World announced its combination with Trump Media (NASDAQ:DJT) back in October 2021, it was clear that SPACworld and the Trump show were set to be intertwined for quite some time. And, although not every headline has a bearing on the wider SPAC world, Trump Media’s post-close rise...
AltC (NYSE:ALCC) has reportedly been taking the pitch deck for its combination with nuclear fission firm Oklo on the road in recent weeks, which has generated the rare result of a SPAC trading significantly above its trust value still well before completing its deal. The SPAC has an estimated $10.59 per share in its trust...